Home / Deep Research / Benign Familial Infantile Epilepsy

Benign Familial Infantile Epilepsy

Benign Familial Infantile Epilepsy Deep Research Fallback

⚠️ Fallback MONDO:0017615

Benign Familial Infantile Epilepsy Deep Research Fallback

Provider Attempts

  • timeout 75s just research-disorder falcon Benign_Familial_Infantile_Epilepsy
  • Result: timed out with Recipe research-disorder was terminated by signal 15.
  • timeout 75s just research-disorder openai Benign_Familial_Infantile_Epilepsy
  • Result: timed out with Recipe research-disorder was terminated by signal 15.

No provider-generated research artifact was available within the bounded window. The YAML therefore was curated directly from MONDO/ORPHA structured records and PubMed abstracts cached via just fetch-reference.

Evidence-backed curation scope

The entry integrates the following deterministic sources:

  • MONDO terms for the disease and its molecular subtypes:
  • MONDO:0017615 benign familial infantile epilepsy (root).
  • MONDO:0011593 seizures, benign familial infantile, 2 (PRRT2-related).
  • MONDO:0011178 infantile convulsions and choreoathetosis (ICCA).
  • MONDO:0011904 seizures, benign familial infantile, 3 (SCN2A-related BFNIS).
  • MONDO:0014903 seizures, benign familial infantile, 5 (SCN8A-related).
  • HGNC gene identifiers: hgnc:30500 PRRT2, hgnc:10588 SCN2A, hgnc:10596 SCN8A.
  • PubMed caches (six PMIDs):
  • PMID:22243967 PRRT2 discovery paper establishing PRRT2 as the major BFIE gene and the shared molecular cause of BFIE and ICCA.
  • PMID:23077018 PRRT2 phenotypic-spectrum cohort confirming PRRT2 mutation frequencies (>80% BFIE, >90% ICCA) and the afebrile, autosomal-dominant infantile-seizure clinical definition.
  • PMID:23343561 review of PRRT2 across paroxysmal neurological disorders, summarising the truncating/haploinsufficiency mutation mechanism and SNAP-25 interaction.
  • PMID:27052163 mechanistic cellular study showing PRRT2 loss impairs Ca2+-dependent synchronous synaptic vesicle release and SNAP-25/synaptotagmin 1/2 interactions.
  • PMID:12243921 original identification of SCN2A as the gene underlying benign familial neonatal-infantile seizures (BFNIS).
  • PMID:38160512 Australian long-term cohort of self-limited familial neonatal/infantile epilepsy reporting genetic yields (PRRT2, KCNQ2, SCN2A, SCN8A), seizure-recurrence rates, late-onset PKD and hemiplegic migraine, antiseizure-medication burden, and Vineland-3 adaptive function outcomes.

Integrated Literature Synthesis

BFIE is an autosomal-dominant, self-limited focal epilepsy of infancy. PMID:22243967 (Heron et al., 2012) established PRRT2 as the dominant gene, identifying heterozygous truncating mutations in 14/17 BFIE families (82%) and in 5/6 ICCA families (83%) and noting the pleiotropy of PRRT2 across age (infancy vs. later childhood) and anatomical substrate (cortex vs. basal ganglia). PMID:23077018 (Ono et al., 2012) independently replicated PRRT2 mutation frequencies (>80% BFIE, >90% ICCA), provided the canonical clinical definition (afebrile autosomal-dominant infantile seizures with onset around 6 months of age), and showed PRRT2 mutations do not extend to other infantile epilepsy syndromes. PMID:23343561 (Ebrahimi-Fakhari et al., 2015) reviews the unifying molecular mechanism: the vast majority of PRRT2 variants are truncating and predicted to cause haploinsufficiency at the presynaptic SNAP-25/SNARE machinery, explaining the shared pathogenesis of BFIE, ICCA, and paroxysmal kinesigenic dyskinesia (PKD). PMID:27052163 (Valente et al., 2016) provides the direct cellular evidence: PRRT2 is enriched at presynaptic terminals, interacts with SNAP-25 and synaptotagmin 1/2, and its loss decreases synapse number, increases docked synaptic vesicles at rest, and severely impairs synchronous Ca2+-dependent neurotransmitter release.

Beyond PRRT2, PMID:12243921 (Heron et al., 2002) identified SCN2A missense variants as the cause of benign familial neonatal-infantile seizures (BFNIS), a clinically intermediate syndrome bridging the neonatal and infantile onset windows. PMID:38160512 (Howell et al., 2024) provides the most comprehensive long-term cohort: 14/15 of their Australian self-limited familial epilepsy families had a genetic diagnosis, with the gene mix PRRT2 (n=4), KCNQ2 (n=3), SCN2A (n=4), and SCN8A (n=2). The same cohort reports that 10/50 individuals had later seizure recurrence (median 11.8-12.8 years after the last infantile seizure), that paroxysmal kinesigenic dyskinesia (5 individuals, 4 families) and hemiplegic migraine (8 individuals, 3 families) emerged later in life, that the majority (82%) of carriers had average Vineland-3 adaptive functioning, and that global developmental delay was associated with older age at last seizure, longer epilepsy duration, and a higher number of antiseizure medications.

Curation Notes

  • The "Seizure Clusters" phenotype uses the generic HP:0001250 (Seizure) with temporality: RECURRENT. The more specific HP:0033349 (Seizure cluster) was considered but is classified under HP:0012823 (Clinical modifier) rather than HP:0000118 (Phenotypic abnormality), so it is not reachable from the PhenotypeTerm enum source nodes. HP:0031796 (Recurrent), the direct parent of HP:0033349, is the meaning of the RECURRENT temporality enum value, so this composition preserves the clinical semantics within the schema.
  • Treatment evidence is intentionally PARTIAL: PMID:38160512 reports ASM burden in this cohort but does not establish first-line agent efficacy. Carbamazepine and oxcarbazepine are captured as therapeutic_agent CHEBI entries based on standard pediatric epilepsy clinical practice for BFIE, while the formal evidence link is anchored to PMID:38160512's documentation of ASM use.
  • KCNQ2-related BFNS was intentionally excluded from has_subtypes because KCNQ2-associated benign familial neonatal seizures are a distinct nosological entity from BFIE proper; PMID:38160512 includes KCNQ2 carriers in its self-limited familial epilepsy cohort but they are not BFIE.